In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Therabel to market Loramyc and Setofilm in Europe

Executive Summary

Following the collapse of its European joint venture with SpePharm Holding BV, BioAlliance Pharma SA (mainly oncology and infectious disease drug candidates) has found a new partner for Loramyc (miconazole) in Europe--spec pharma Therabel Pharma NV Holding, which will have exclusive rights to market the antifungal in addition to BioAlliance's anti-emetic Setofilm (ondansetron). Therabel's newly created division Therabel Hopital Pharma will be responsible for marketing the drugs in France.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register